Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Knox

Showing results (761-770 of 829) with videos related to

Pageof 83
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|September 7, 2021
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced CancerCamilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Bioorganic & Medicinal Chemistry|August 19, 2017
Discovery of non-zwitterionic aryl sulfonamides as Na<sub>v</sub>1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activationYong-Jin Wu, Jason Guernon, Andrea McClure, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|November 16, 2016
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypesSamir R Shah, P N Rao, Shiv K Sarin, et al.
Cell Reports. Medicine|December 20, 2023
Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodiesZheng Zhang, Caroline Markmann, Ming Yu, et al.
Journal of Medicinal Chemistry|February 25, 2017
Development of New Benzenesulfonamides As Potent and Selective Na<sub>v</sub>1.7 Inhibitors for the Treatment of PainYong-Jin Wu, Jason Guernon, Jianliang Shi, et al.
Nature Communications|August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Carlos H Barrios, Tae Min Kim, et al.
British Journal of Cancer|March 17, 2023
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinomaLucy X Ma, Yifan Wang, Osvaldo Espin-Garcia, et al.
Nature Communications|March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, James T Topham, Jonathan M Loree, et al.
Pageof 83

Showing results (761-770 of 829) with videos related to

Sort By:
Pageof 83
Journal of the National Comprehensive Cancer Network : JNCCN|September 7, 2021
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced CancerCamilla Zimmermann, Ashley Pope, Breffni Hannon, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Bioorganic & Medicinal Chemistry|August 19, 2017
Discovery of non-zwitterionic aryl sulfonamides as Na<sub>v</sub>1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activationYong-Jin Wu, Jason Guernon, Andrea McClure, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|November 16, 2016
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypesSamir R Shah, P N Rao, Shiv K Sarin, et al.
Cell Reports. Medicine|December 20, 2023
Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodiesZheng Zhang, Caroline Markmann, Ming Yu, et al.
Journal of Medicinal Chemistry|February 25, 2017
Development of New Benzenesulfonamides As Potent and Selective Na<sub>v</sub>1.7 Inhibitors for the Treatment of PainYong-Jin Wu, Jason Guernon, Jianliang Shi, et al.
Nature Communications|August 26, 2022
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, Jonathan M Loree, Jennifer J Knox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Carlos H Barrios, Tae Min Kim, et al.
British Journal of Cancer|March 17, 2023
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinomaLucy X Ma, Yifan Wang, Osvaldo Espin-Garcia, et al.
Nature Communications|March 7, 2026
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinomaDaniel J Renouf, James T Topham, Jonathan M Loree, et al.
Pageof 83